Navigation Links
Triple Negative Cancer Research Could Benefit All Breast Cancer Patients
Date:1/31/2011

FREDERICKSBURG, Va., Jan. 31, 2011 /PRNewswire/ -- Research to develop more effective treatments for triple negative breast cancer -- a difficult disease to cure -- could someday benefit all breast cancer patients, reports Dr. Frederick C. Tucker, Jr. of Fredericksburg Oncology.

"Understanding how triple negative cancers spread in the absence of normal growth factors may give us insight into how other types of breast cancer grow and spread even after treatment," Dr. Tucker explains.

Recent research has shown that a new class of drugs, PARP inhibitors, can be combined with chemotherapy to kill more triple negative breast cancer cells. Research also indicates that platinum compounds, a type of chemotherapy not typically prescribed for breast cancer, may be useful in treating triple negative disease.

Currently, two trials offered at Fredericksburg Oncology focus on triple negative disease.

  • CALGB 40603:  Pre-operative (neoadjuvant) chemotherapy for triple-negative breast cancer involving platinum chemotherapy (carboplatin) and bevacizumab.
  • NCCTG N0937:  Platinum chemotherapy (Cisplatin) and brostacillin for metastatic triple-negative breast cancer

An estimated 15 percent of breast cancers are triple negative, meaning they do not have receptors for estrogen, progesterone, and for the growth factor receptor HER2.  Breast cancer treatments such as Tamoxifen, Arimidex, Femara, and Herceptin which target these molecules are therefore not helpful against triple negative disease. Standard chemotherapies can be used in triple negative breast cancer, but they may not be as effective as they are for more common breast cancers.

For more information about clinical trials offered through Fredericksburg Oncology, visit http://fredericksburgoncology.com/wp/about-clinical-trials/.  Email regarding clinical trials can be sent to info@fred-onc.com or call (540) 368-0500.

About Fredericksburg Oncology

Fredericksburg Oncology specializes in providing high quality treatment for the medical and emotional needs of cancer patients. Since 2006, the practice also has been committed to providing clinical research. It is located at 111 Park Hill Drive, Suite B, Fredericksburg, VA 22401 near Mary Washington Hospital. For more information call (540) 368-0500 or visit www.fredericksburgoncology.com.

Dr. Frederick C. Tucker, Jr. is board certified in oncology, internal medicine, and psychiatry. He also is a writer and speaker on cancer-related topics. To read Dr. Tucker's recent commentary, visit http://fredericksburgoncology.com/wp/topics/news/ or connect with him on Facebook.


'/>"/>
SOURCE Fredericksburg Oncology
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer
2. Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine
3. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
4. By 2019, the Acute Gout Drug Market Will Triple in Size While the Chronic Gout Drug Market Will Reach $1.83 Billion
5. The Hepatitis C Virus Drug Market Will More Than Triple by 2014 but, Thereafter, the Market Will Decline Substantially Through 2019 Due to Decreasing Disease Prevalence and the High Efficacy of New Treatments
6. The Hepatitis C Virus Drug Market Will Nearly Triple by 2014 but, Thereafter, the Market Will Decline Substantially Through 2019 Due to Decreasing Disease Prevalence and the High Efficacy of New Treatments
7. Reportlinker Adds Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors
8. EndoChoice® Triples Facility Space to Address Growing Customer Base
9. New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes
10. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
11. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):